Published in Cancer Res on April 15, 2002
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol (2003) 2.59
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol (2002) 2.50
HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. Virchows Arch (2016) 2.11
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate (2004) 1.43
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate (2008) 1.42
Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006) 1.39
Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer (2011) 1.39
Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics (2006) 1.39
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate (2011) 1.34
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol (2002) 1.34
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
High-grade prostatic intraepithelial neoplasia. Rev Urol (2004) 1.18
Localization of P. gingivalis in preterm delivery placenta. J Dent Res (2009) 1.15
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol (2004) 1.15
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer (2008) 1.13
A perspective on DNA microarrays in pathology research and practice. Am J Pathol (2007) 1.11
A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med (2007) 1.09
Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr (2012) 1.07
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol (2012) 1.05
Urinary biomarkers for prostate cancer: a review. Asian J Androl (2013) 1.02
Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues. J Histochem Cytochem (2010) 1.01
Polymorphism analysis of six selenoprotein genes: support for a selective sweep at the glutathione peroxidase 1 locus (3p21) in Asian populations. BMC Genet (2006) 1.01
Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol (2003) 1.00
Using rule-based machine learning for candidate disease gene prioritization and sample classification of cancer gene expression data. PLoS One (2012) 1.00
Diagnostic utility of α-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer. Diagn Pathol (2010) 0.99
NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol (2010) 0.97
Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl (2012) 0.96
Lipid metabolism in prostate cancer. Am J Clin Exp Urol (2014) 0.96
Prostate-specific antigen: any successor in sight? Rev Urol (2013) 0.95
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. Biomed Res Int (2013) 0.93
Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol (2008) 0.93
Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci (2014) 0.92
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology (2011) 0.91
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. Oncotarget (2014) 0.90
Mitochondrial DNA as a potential tool for early cancer detection. Hum Genomics (2006) 0.90
Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics (2013) 0.90
Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol (2003) 0.89
Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate (2013) 0.89
A microRNA code for prostate cancer metastasis. Oncogene (2015) 0.89
High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). Mol Cancer Ther (2011) 0.89
HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch (2013) 0.89
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene (2014) 0.86
Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem (2011) 0.86
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol (2009) 0.86
α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC. J Clin Pathol (2014) 0.86
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res (2008) 0.86
Interrogating genomic and epigenomic data to understand prostate cancer. Biochim Biophys Acta (2012) 0.85
Prostatic intraepithelial neoplasia: an overview. Rev Urol (2005) 0.85
Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database. Surg Today (2012) 0.84
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet (2009) 0.84
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate (2010) 0.84
Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation. Oncotarget (2016) 0.83
Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Hum Pathol (2009) 0.83
Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue. Am J Pathol (2015) 0.83
Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate (2012) 0.82
Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors. Virchows Arch (2004) 0.81
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med (2013) 0.81
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues. Biomed Res Int (2013) 0.81
Examining the relationship between obesity and prostate cancer. Rev Urol (2004) 0.81
α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate (2011) 0.81
Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol (2006) 0.80
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med (2009) 0.80
Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep (2016) 0.79
High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer. Int J Clin Exp Med (2015) 0.79
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther (2014) 0.79
Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate. Korean J Urol (2010) 0.79
Roles of the Y chromosome genes in human cancers. Asian J Androl (2015) 0.78
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens. Virchows Arch (2006) 0.78
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer. Genes (Basel) (2010) 0.77
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer? BMC Cancer (2005) 0.77
[Immunohistochemical algorithms in prostate diagnostics: what's new?]. Pathologe (2009) 0.77
Genetic variations of α -methylacyl-CoA racemase are associated with sporadic prostate cancer risk in ethnically homogenous Koreans. Biomed Res Int (2013) 0.77
Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas. Hum Pathol (2013) 0.77
Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy. J Mol Histol (2006) 0.77
Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles. Br J Cancer (2011) 0.77
Living Cell Microarrays: An Overview of Concepts. Microarrays (Basel) (2016) 0.77
Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer. Prostate (2010) 0.76
Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate. Prostate (2015) 0.76
A New Combinatorial Optimization Approach for Integrated Feature Selection Using Different Datasets: A Prostate Cancer Transcriptomic Study. PLoS One (2015) 0.76
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. J Cancer (2016) 0.76
Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. J Histochem Cytochem (2016) 0.75
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. BMC Urol (2016) 0.75
Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer? Nephrourol Mon (2016) 0.75
The expressions of AMACR and iNOS in prostate adenocarcinomas. Pak J Med Sci (2013) 0.75
A study on the AMACR catalysed elimination reaction and its application to inhibitor testing. Org Biomol Chem (2015) 0.75
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. J Biomark (2014) 0.75
Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. Oncotarget (2015) 0.75
Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate (2016) 0.75
Co-existence of mucin-producing urothelial-type adenocarcinoma of the prostate and inverted papilloma of the bladder. Contemp Oncol (Pozn) (2017) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell (2002) 5.23
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999-2004. Arch Intern Med (2008) 4.40
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer (2007) 3.77
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell (2006) 3.53
Monocarboxylate transporter 1 deficiency and ketone utilization. N Engl J Med (2014) 3.36
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res (2002) 3.19
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Prevalence and risk factors for erectile dysfunction in the US. Am J Med (2007) 2.84
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst (2009) 2.50
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab (2007) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 2.26
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate (2011) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate (2005) 2.18
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. Am J Epidemiol (2004) 2.08